Compare · UFPT vs WST
UFPT vs WST
Side-by-side comparison of UFP Technologies Inc. (UFPT) and West Pharmaceutical Services Inc. (WST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both UFPT and WST operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- WST is the larger of the two at $25.31B, about 13.5x UFPT ($1.87B).
- Over the past year, UFPT is up 5.9% and WST is up 70.4% - WST leads by 64.5 points.
- WST has been more active in the news (5 items in the past 4 weeks vs 2 for UFPT).
- WST has more recent analyst coverage (18 ratings vs 7 for UFPT).
- Company
- UFP Technologies Inc.
- West Pharmaceutical Services Inc.
- Price
- $241.86-5.71%
- $358.18-1.11%
- Market cap
- $1.87B
- $25.31B
- 1M return
- +4.40%
- +8.72%
- 1Y return
- +5.92%
- +70.45%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 1993
- News (4w)
- 2
- 5
- Recent ratings
- 7
- 18
UFP Technologies Inc.
UFP Technologies, Inc. designs and converts foams, films, and plastics materials for the medical, automotive, consumer, electronics, industrial, and aerospace and defense markets in the United States. It offers single patient use surfaces, advanced wound care, infection prevention, and disposables for surgical procedures, endoscopic procedures, orthopedic implants, orthopedic appliances, biopharma drug manufacturing, etc.; molded components for automotive, aerospace, and defense markets; recycled protective packaging for B2C brands; and reusable cases and custom inserts. The company markets and sells its products through direct sales forces and independent manufacturer representatives. UFP Technologies, Inc. was founded in 1963 and is headquartered in Newburyport, Massachusetts.
West Pharmaceutical Services Inc.
West Pharmaceutical Services, Inc. designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
Latest UFPT
- Amendment: SEC Form SCHEDULE 13G/A filed by UFP Technologies Inc.
- UFP Technologies, Inc. to Present and Host 1x1 Investor Meetings at the CJS Securities 26th Annual New Ideas Summer Conference
- Director Feldmann Cynthia L exercised 1,200 shares at a strike of $43.95 and sold $287,149 worth of shares (1,200 units at $239.29) (SEC Form 4)
- UFP Technologies Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Executive Chairman Bailly R Jeffrey was granted 1,787 shares and covered exercise/tax liability with 750 shares, increasing direct ownership by 0.61% to 171,200 units (SEC Form 4)
- SVP Human Resources Stafford Ryan K was granted 1,448 shares (SEC Form 4)
- New insider Stafford Ryan K claimed no ownership of stock in the company (SEC Form 3)
- UFP Technologies Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Chief Financial Officer Lataille Ronald J was granted 4,454 shares, increasing direct ownership by 28% to 20,352 units (SEC Form 4)
- President Rock Mitchell was granted 2,895 shares, increasing direct ownership by 8% to 39,115 units (SEC Form 4)
Latest WST
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- BNP Paribas Exane initiated coverage on West Pharm with a new price target
- West to Host Second-Quarter 2026 Conference Call
- SEC Form 4 filed by Director Haugen Janet Brutschea
- West Completes Sale and Transfer of the Manufacturing and Supply Rights for SmartDose® 3.5mL On-Body Delivery System
- West Pharm upgraded by Barclays with a new price target
- Wolfe Research resumed coverage on West Pharm with a new price target
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- West Appoints Michel Lagarde to be President and Chief Executive Officer
- Amendment: West Pharmaceutical Services Inc. filed SEC Form 8-K: Financial Statements and Exhibits